# Ingo K. Mellinghoff

Source: https://onco.cc/people/ingo-mellinghoff/  
OnCo record `ingo-mellinghoff` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma.

## Summary

Ingo Mellinghoff was principal investigator of INDIGO, which showed the dual IDH1/2 inhibitor vorasidenib more than doubles progression-free survival and delays the need for chemoradiotherapy in grade 2 IDH-mutant glioma, the first targeted drug approved for glioma and a shift away from early radiation for young patients. His laboratory studies signalling and metabolism in glioma and he leads neuro-oncology drug development at MSKCC.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: glioma; idh; targeted-therapy
- Role: Chair, Department of Neurology, Memorial Sloan Kettering Cancer Center
- Specialisms: Glioma; IDH-mutant tumours; Targeted therapy; Neuro-oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Mellinghoff%20IK%5BAuthor%5D%20glioma%20vorasidenib

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- targets: [IDH1 / IDH2](https://onco.cc/targets/idh/)
- drugs: [Vorasidenib](https://onco.cc/drugs/vorasidenib/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [INDIGO](https://onco.cc/trials/indigo/)
- key papers: [INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma](https://onco.cc/key-papers/paper-indigo-nejm-2023/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/ingo-mellinghoff.json